Access Statistics for Rena Marie Conti

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market 0 0 0 13 3 8 11 41
Early Retirement and Public Disability Insurance Applications: Exploring the Impact of Depression 0 0 0 61 1 1 1 445
Estimating the Financial Impact of Gene Therapy in the U.S 0 0 0 15 5 16 23 77
Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets 0 0 0 15 1 5 6 33
Pricing in the Market for Anticancer Drugs 0 0 0 59 2 6 7 115
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007 0 0 0 80 0 6 6 79
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts 0 0 0 16 1 6 8 86
The Generic Drug User Fee Amendments: An Economic Perspective 0 0 0 40 1 7 10 54
The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications 0 0 0 7 1 6 9 33
The Landscape of US Generic Prescription Drug Markets, 2004-2016 0 0 1 88 0 3 11 123
The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration 0 0 0 37 4 10 17 81
Valuing Rare Pediatric Drugs: An Economics Perspective 0 0 0 14 0 4 6 49
Total Working Papers 0 0 1 445 19 78 115 1,216

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Four Facts Concerning Competition in US Generic Prescription Drug Markets 0 0 0 5 0 3 6 28
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US 2 3 3 12 3 5 8 62
Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities 0 0 0 0 1 1 1 4
Pricing in the Market for Anticancer Drugs 0 0 0 21 1 4 5 139
RESPONSE TO JOYCE AND SOOD 0 0 0 3 0 0 0 28
Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” 1 1 1 2 1 1 2 18
Stockpiling at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices 0 0 0 0 0 3 10 15
THE ADVANTAGES OF AWARDING THE FEDERAL GOVERNMENT NEGOTIATING POWER OVER THE PRICES OF PRESCRIPTION DRUGS 0 0 0 20 0 1 1 55
The Economics of Generic Drug Shortages: The Limits of Competition 0 2 7 7 3 13 38 38
Total Journal Articles 3 6 11 70 9 31 71 387

Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Early Retirement and DI/SSI Applications: Exploring the Impact of Depression 0 0 0 15 0 3 4 53
How do Initial Signals of Quality Influence the Diffusion of New Medical Products? The Case of New Cancer Drug Treatments 0 0 0 2 0 2 4 9
Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007 0 0 1 28 2 5 9 110
Total Chapters 0 0 1 45 2 10 17 172

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-03-04